Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 2
2007 1
2011 3
2012 3
2013 4
2014 2
2016 3
2017 1
2018 2
2019 3
2020 2
2021 5
2022 6
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: kahatt c. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, Farago AF, López-Vilariño JA, Cullell-Young M, Nieto A, Vasco N, Gómez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sánchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Dómine M, Paz-Ares L. Aix SP, et al. Among authors: kahatt c. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. Lancet Respir Med. 2023. PMID: 36252599 Clinical Trial.
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L. Farago AF, et al. Among authors: kahatt c. Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26. Future Oncol. 2019. PMID: 30362375 Free PMC article. Clinical Trial.
Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J, Modrego A, Zeaiter A, Kahatt C, Alfaro V, Jimenez-Aguilar E, Mazarico JM, Paz-Ares L. Baena J, et al. Among authors: kahatt c. Future Oncol. 2021 Jun;17(18):2279-2289. doi: 10.2217/fon-2020-1212. Epub 2021 Mar 19. Future Oncol. 2021. PMID: 33736462 Review.
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Longo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-García E, Awada A, Santaballa A, Subbiah V. Longo-Muñoz F, et al. Among authors: kahatt c. Eur J Cancer. 2022 Sep;172:340-348. doi: 10.1016/j.ejca.2022.06.024. Epub 2022 Jul 10. Eur J Cancer. 2022. PMID: 35830841 Free article. Clinical Trial.
Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.
Astorgues-Xerri L, Vázquez R, Odore E, Rezai K, Kahatt C, Mackenzie S, Bekradda M, Coudé MM, Dombret H, Gardin C, Lokiec F, Raymond E, Noel K, Cvitkovic E, Herait P, Bertoni F, Riveiro ME. Astorgues-Xerri L, et al. Among authors: kahatt c. Leuk Lymphoma. 2019 Dec;60(12):3067-3070. doi: 10.1080/10428194.2019.1617860. Epub 2019 Jun 17. Leuk Lymphoma. 2019. PMID: 31204545 No abstract available.
Acute myeloid leukemia unlikely related to trabectedin treatment.
Cartoafa M, Kahatt C, Soto-Matos A, Roy E, Lardelli P. Cartoafa M, et al. Among authors: kahatt c. Acta Haematol. 2011;126(4):238-9; author reply 240. doi: 10.1159/000330952. Epub 2011 Sep 24. Acta Haematol. 2011. PMID: 21952689 No abstract available.
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Calvo E, Sessa C, Harada G, de Miguel M, Kahatt C, Luepke-Estefan XE, Siguero M, Fernandez-Teruel C, Cullell-Young M, Stathis A, Drilon A. Calvo E, et al. Among authors: kahatt c. Invest New Drugs. 2022 Dec;40(6):1263-1273. doi: 10.1007/s10637-022-01281-z. Epub 2022 Aug 10. Invest New Drugs. 2022. PMID: 35947247 Free PMC article. Clinical Trial.
37 results